Asthma is big business for Big Pharma. Advair was the third best selling drug in the world in 2013 and the asthma drugs Singulair and Symbicort were also blockbusters. So it is no surprise the prospect of a high-tech injectable drug that stops an allergic response by binding to immunoglobulin E (IgE) made Big Pharma sit up and take notice. Continue reading → Bev Conover Editor & Publisher Intrepid Report https://www.intrepidreport.com https://www.facebook.com/intrepidreport http://twitter.com/#!/Intrepid_Report [email protected]